Open Access<p>Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer</p>
Author(s) -
Satoshi Igawa,
Taihei Ono,
Masashi Kasajima,
Hideaki Manabe,
Tomoya Fukui,
Hisashi Mitsufuji,
Masanori Yokoba,
Minoru Kubota,
Masato Katagiri,
Jiichiro Sasaki,
Katsuhiko Naoki
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s255552
Subject(s) - medicine , neutropenia , chemotherapy , febrile neutropenia , lung cancer , carboplatin , etoposide , performance status , gastroenterology , oncology , cisplatin
Amrubicin (AMR) is an anticancer drug for patients with relapsed small-cell lung cancer (SCLC). However, the efficacy of AMR in elderly patients with relapsed SCLC after chemotherapy by carboplatin plus etoposide (CE) has not been sufficiently evaluated.